Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncology Dominates Japan Approvals, Though Overall Tally Is Lower

Executive Summary

Although it approved fewer new products last fiscal year, Japan granted access to a number of important new therapies, including in oncology and several for the first time worldwide, helped by continuing reforms at its regulatory body.

You may also be interested in...

Japan’s Crossroads: PhRMA’s Scangos Warns Of Policy Change Fallout

The foreign research-based pharma industry in Japan is continuing to ramp up warnings about what it sees as possible negative changes to Japan's currently "stable and predictable" pricing and operating environment, with the new chairman of US group PhRMA the latest to weigh in on the debate.

Japan PMDA To Kick Off New Asia Training Center

Japan's regulatory body will set up a new center next month to help in the training of other drug and device authorities across Asia, as part of its growing international activities.

Japan First To Approve Omarigliptin, Lusutrombopag

The latest batch of product approvals in Japan includes the first regulatory clearances worldwide for new molecules from Merck and Shionogi, in a further sign that the country's "drug lag" is a thing of the past.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts